产品: 磷酸化 Pim-1 (Tyr309) 抗体
货号: AF3922
描述: Rabbit polyclonal antibody to Phospho-Pim-1 (Tyr309)
应用: ELISA(peptide)
反应: Human, Mouse, Rat
分子量: 36kD(Calculated).
蛋白号: P11309
RRID: AB_2847645

浏览相似产品>>

   规格 价格 库存
 100ul RMB¥ 2800 现货
 200ul RMB¥ 3800 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
ELISA(peptide) 1:20000-1:40000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human,Mouse,Rat
克隆:
Polyclonal
特异性:
Phospho-Pim-1 (Tyr309) Antibody detects endogenous levels of Pim-1 only when phosphorylated at Tyr309.
RRID:
AB_2847645
引用格式: Affinity Biosciences Cat# AF3922, RRID:AB_2847645.
偶联:
Unconjugated.
纯化:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Oncogene PIM 1; Oncogene PIM1; PIM 1; pim 1 kinase 44 kDa isoform; Pim 1 kinase; pim 1 oncogene (proviral integration site 1); Pim 1 oncogene; PIM; PIM1; pim1 kinase 44 kDa isoform; PIM1_HUMAN; Pim2; PIM3; Proto oncogene serine/threonine protein kinase Pim 1; Proto-oncogene serine/threonine-protein kinase Pim-1; Proviral integration site 1; Proviral integration site 2;

抗原和靶标

免疫原:

A synthesized peptide derived from human Pim-1 around the phosphorylation site of Tyr309.

Uniprot:
基因/基因ID:
表达:
P11309 PIM1_HUMAN:

Expressed primarily in cells of the hematopoietic and germline lineages. Isoform 1 and isoform 2 are both expressed in prostate cancer cell lines.

序列:
MLLSKINSLAHLRAAPCNDLHATKLAPGKEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSK

翻译修饰 - P11309 作为底物

Site PTM Type Enzyme
K5 Ubiquitination
S8 Phosphorylation
T23 Phosphorylation
K24 Ubiquitination
K31 Ubiquitination
S46 Phosphorylation
K67 Ubiquitination
K94 Ubiquitination
S98 Phosphorylation
K169 Ubiquitination
K183 Ubiquitination
S189 Phosphorylation P11309 (PIM1)
K194 Ubiquitination
S261 Phosphorylation
S308 Phosphorylation

翻译修饰 - P11309 作为激酶

Substrate Site Source
O14757 (CHEK1) S280 Uniprot
O43524 (FOXO3) T32 Uniprot
O43524 (FOXO3) S253 Uniprot
P01106 (MYC) S329 Uniprot
P10275 (AR) S215 Uniprot
P10275 (AR) T851 Uniprot
P11309 (PIM1) S189 Uniprot
P27448-3 (MARK3) T90 Uniprot
P27448 (MARK3) T95 Uniprot
P27448-3 (MARK3) S96 Uniprot
P30304-1 (CDC25A) S116 Uniprot
P36888 (FLT3) Y591 Uniprot
P38936 (CDKN1A) T145 Uniprot
P38936 (CDKN1A) S146 Uniprot
P46527 (CDKN1B) T157 Uniprot
P46527 (CDKN1B) T198 Uniprot
P61073 (CXCR4) S339 Uniprot
P68431 (HIST1H3J) S11 Uniprot
Q00987 (MDM2) S166 Uniprot
Q00987 (MDM2) S186 Uniprot
Q01860 (POU5F1) S288 Uniprot
Q01860 (POU5F1) S289 Uniprot
Q04206 (RELA) S276 Uniprot
Q12778 (FOXO1) T24 Uniprot
Q12778 (FOXO1) S256 Uniprot
Q12778 (FOXO1) S319 Uniprot
Q13309 (SKP2) S64 Uniprot
Q13309 (SKP2) S72 Uniprot
Q13309 (SKP2) T417 Uniprot
Q13761 (RUNX3) S149 Uniprot
Q13761 (RUNX3) T151 Uniprot
Q13761 (RUNX3) T153 Uniprot
Q13761 (RUNX3) T155 Uniprot
Q8TA86 (RP9) S212 Uniprot
Q8TA86 (RP9) S214 Uniprot
Q92934 (BAD) S75 Uniprot
Q92934 (BAD) S99 Uniprot
Q92934 (BAD) S118 Uniprot
Q96B36 (AKT1S1) T246 Uniprot
Q99683 (MAP3K5) S83 Uniprot
Q99801 (NKX3-1) T89 Uniprot
Q99801 (NKX3-1) S185 Uniprot
Q99801 (NKX3-1) S186 Uniprot
Q99801 (NKX3-1) S195 Uniprot
Q99801 (NKX3-1) S196 Uniprot
Q9BZS1 (FOXP3) S422 Uniprot
Q9UNQ0 (ABCG2) T362 Uniprot

研究背景

功能:

Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promotes cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B, induces 14-3-3 proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis. Also phosphorylates and activates the ATP-binding cassette transporter ABCG2, allowing resistance to drugs through their excretion from cells.

翻译修饰:

Autophosphorylated on both serine/threonine and tyrosine residues. Phosphorylated. Interaction with PPP2CA promotes dephosphorylation.

Ubiquitinated, leading to proteasomal degradation.

细胞定位:

Cytoplasm. Nucleus.

Cell membrane.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Expressed primarily in cells of the hematopoietic and germline lineages. Isoform 1 and isoform 2 are both expressed in prostate cancer cell lines.

亚基结构:

Isoform 1 is isolated as a monomer whereas isoform 2 complexes with other proteins (By similarity). Binds to RP9 (By similarity). Isoform 2, but not isoform 1, binds BMX. Isoform 1 interacts with CDKN1B and FOXO3. Interacts with BAD (By similarity). Interacts with PPP2CA; this interaction promotes dephosphorylation of PIM1, ubiquitination and proteasomal degradation. Interacts with HSP90AA1, this interaction stabilizes PIM1 protein levels. Interacts (ubiquitinated form) with HSP70 and promotes its proteosomal degradation. Interacts with CDKN1A. Interacts with CDC25C. Interacts (via N-terminal 96 residues) with CDC25A (By similarity). Interacts with MAP3K5. Interacts with MYC (By similarity). Interacts with CBX3.

蛋白家族:

Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. PIM subfamily.

研究领域

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.